74 results on '"Schwabl, Philipp"'
Search Results
2. WED-089-YI Characterising the hemodynamic and pro-inflammatory profile of a CCl4/LPS-induced acute-on-chronic liver failure (ACLF) rat model
3. THU-540 Characterization of in vivo mouse models of regressive fibrosis and resolving portal hypertension
4. THU-071 Impact of underlying portal hypertension and systemic inflammation on acute-on-chronic liver failure (ACLF) severity and outcome
5. WED-125 Differential regulation of soluble guanylate cyclase signaling during liver fibrosis regression
6. Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist
7. Systemic inflammation remains a critical determinant of the dynamic component of portal hypertension in abstinent patients with alcohol-related cirrhosis
8. TIPS increases muscle mass in patients with decompensated cirrhosis
9. Diabetes impairs the hemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes for hepatic decompensation
10. Dysregulation of the FXR-FGF19 pathway indicates impaired gut-liver axis signalling in patients with cirrhosis
11. Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis
12. Perspectives on environmental heterogeneity and seasonal modulation of stress response in neotropical birds
13. Bacterial translocation has an early onset in cirrhosis and induces a selective inflammatory response
14. Spontaneous portosystemic shunts (SPSS) regress after transjugular intrahepatic portosystemic shunt (TIPS) implantation
15. Collagen-proportionate area determined by semiautomated histomorphometry correlates with HVPG across different liver disease etiologies
16. Distinct patterns of hepatic and systemic inflammation in different types/aetiologies of liver disease
17. 3D Extracellular matrix human liver hydrogels for the investigation of genetic variants in hepatic stellate cells
18. Metabolomic profiles facilitate differential diagnosis of porto-sinusoidal vascular disorder versus liver cirrhosis
19. Decreased platelet function is an independent predictor of liver-related and all-cause mortality in patients with advanced chronic liver disease
20. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
21. Transcriptomic Signatures of Progressive and Regressive Liver Fibrosis and Portal Hypertension
22. Non-invasive tests for clinically significant portal hypertension after HCV cure
23. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis
24. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension
25. Hemodynamic, molecular, and histological characterization of a toxic liver fibrosis regression model
26. The ‘Viennese epidemic’ of acute HCV in the era of direct-acting antivirals
27. In silico characterization of the interactome of hepatic nonparenchymal cells reveals promising targets for antifibrotic therapy
28. Soluble guanylyl cyclase expression and signaling in different types of liver fibrosis
29. Dual inhibition of integrins alpha-v/beta-6 and alpha-v/beta-1 decreases portal pressure and liver fibrosis in rats with biliary cirrhosis
30. Impact of alcohol abstinence in patients with alcohol-related cirrhosis and portal hypertension
31. Hepatic recompensation according to Baveno VII criteria significantly reduces liver-related mortality in patients with decompensated alcohol-related cirrhosis
32. Portal hypertension-associated clinical features in patients with primary biliary cholangitis are of distinct prognostic value
33. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death
34. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
35. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension
36. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension
37. Nuclear receptors in liver fibrosis
38. Molecular surveillance of malaria scales up
39. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
40. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease
41. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy
42. Comparison of the diagnostic quality of aspiration and core biopsy needles for transjugular liver biopsy
43. Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension
44. Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies
45. Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension
46. Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response
47. Bacterial translocation-induced inflammation promotes liver fibrogenesis in patients with advanced chronic liver disease
48. Angiopoietin 2 levels decrease with SVR and correlate with dynamics of portal hypertension in patients with HCV-induced advanced chronic liver disease
49. Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies
50. Distinct features of the portalhypertensive syndrome in patients with advanced chronic liver disease due to non-alcoholic steatohepatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.